NYSE · WATHealthcareLab Analytical Instruments

Waters financials

$443.26+0.07%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jul 4
Q1 '26
Apr 4
Q4 '25
Dec 31
Q3 '25
Sep 27
Q2 '25
Jun 28
Q1 '25
Mar 29
Q4 '24
Dec 31
Q3 '24
Sep 28
Q2 '24
Jun 29
Q1 '24
Mar 30
Q4 '23
Dec 31
Q3 '23
Sep 30
Revenue$1.65B$1.27B$932.4M$799.9M$771.0M$662.0M$872.7M$740.3M$708.5M$636.8M$819.5M$711.7M
Gross profit$734.0M$588.0M$569.5M$472.1M$450.0M$385.0M$524.2M$438.6M$420.3M$375.1M$501.1M$420.3M
Gross margin44.6%46.4%61.1%59.0%58.4%58.2%60.1%59.3%59.3%58.9%61.2%59.1%
Operating income-$86.0M-$47.0M$270.5M$192.1M$188.0M$152.0M$292.3M$211.1M$189.1M$133.8M$264.2M$179.4M
Net income-$136.0M-$72.0M$225.2M$148.9M$147.0M$121.0M$231.4M$161.5M$142.7M$102.2M$216.2M$134.6M
Net margin−8.3%−5.7%24.2%18.6%19.1%18.3%26.5%21.8%20.1%16.0%26.4%18.9%
Diluted EPS$-1.39$-0.87$3.76$2.50$2.47$2.03$3.87$2.71$2.40$1.72$3.63$2.27
EBITDA-$173.0M$160.0M$323.1M$244.8M$185.0M$202.0M$340.8M$260.0M$248.1M$204.4M$276.4M$239.3M
Operating cash flow$201.0M-$3.0M$164.6M$187.3M$41.0M$260.0M$240.1M$204.6M$54.5M$262.9M$230.1M$157.8M
Free cash flow$153.0M-$42.0M$125.6M$161.9M$18.0M$234.0M$188.0M$179.0M$18.4M$234.2M$230.1M$157.8M
Diluted shares98.2M82.1M59.8M59.6M59.7M59.7M59.8M59.5M59.5M59.4M59.5M59.3M

Balance sheet

Period endJul 4Apr 4Dec 31Sep 27Jun 28Mar 29
Cash & equivalents$539.0M$462.0M$588.0M$459.1M$367.2M$382.9M
Short-term investments$0.00$0.00$0.00$0.00$0.00$0.00
Total debt$5.09B$5.21B$1.41B$1.41B$1.46B$1.46B
Total assets$24.75B$24.53B$5.08B$4.86B$4.72B$4.59B
Total liabilities$9.56B$9.24B$2.52B$2.53B$2.56B$2.63B
Shareholders' equity$15.20B$15.29B$2.56B$2.33B$2.16B$1.96B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology